SYF Synchrony Financial
Great card franchise, but $71 prices in peak-cycle returns; mid-teens normalized ROE implies about $65.
The story
Synchrony is the largest US private-label and co-brand card issuer. Its partner network (Lowe's, Amazon, PayPal, CareCredit, now growing in vet care through Vetspire) gives it sticky origination and net interest margins near 15%. Trailing ROE of about 22.6% comes from late-cycle conditions: charge-offs are easing from their 2024 peak, reserves are being released and buybacks are heavy. Through the cycle, subprime-leaning revolving credit plus regulatory pressure on late fees point to mid-teens returns. Revenue has flattened (15.06B to 14.98B), which suggests loan growth is stalling as the company tightens underwriting.
No material new facts since the 2026-09-25 take. Vetspire is a small partner win and doesn't change normalized returns, so I kept ROE at 15.5% against a cost of equity of about 10.9%. That is a positive spread, but well below the trailing 22.6% because card losses mean-revert. Book grows slowly because most earnings go out as buybacks and dividends, and beta of 1.25 sits just above the consumer-finance anchor to reflect the credit tilt toward weaker borrowers.
Value drivers
| Return on equity (normalized) | 15.5% |
| Book-value growth (Y1) | 3.0% |
| Terminal book growth | 4.0% |
| Beta | 1.25 |
| Failure probability | 3.0% |
| Cost of equity | 10.9% |
Valuation bridge
| PV of excess returns | 3.59B |
| PV of terminal excess | 2.25B |
| Equity value | 20.74B |
| ÷ shares → per share | $63.74 |
News
bullish +0.60 · 8 articles
- Synchrony Financial (SYF) Could Be 20% Below Fair Value Following Vetspire Partnership
- How Can Trust Shape Synchrony Financial's AI Shopping Opportunity?
- The Bull Case For Synchrony Financial (SYF) Could Change Following New Vetspire Tie-Up And AI Study
- 1 of Wall Street’s Favorite Stocks with Exciting Potential and 2 We Find Risky
- Major lender prepares for a surprising shift in how Americans shop
- Is Synchrony Financial Stock Underperforming the Nasdaq?
- Synchrony Financial Sees Resilient Spending, Reaffirms Receivables Growth Outlook
- 3 Reasons SYF Has Explosive Upside Potential
Projected excess returns on equity
| Yr | Book equity | ROE | Excess return | PV |
|---|---|---|---|---|
| 1 | 15.54B | 15.5% | 712.23M | 642.12M |
| 2 | 16.01B | 15.2% | 687.66M | 558.95M |
| 3 | 16.51B | 14.9% | 661.69M | 484.90M |
| 4 | 17.04B | 14.6% | 634.13M | 418.96M |
| 5 | 17.61B | 14.4% | 604.75M | 360.22M |
| 6 | 18.21B | 14.1% | 573.32M | 307.88M |
| 7 | 18.86B | 13.8% | 539.59M | 261.25M |
| 8 | 19.55B | 13.5% | 503.28M | 219.68M |
| 9 | 20.29B | 13.2% | 464.08M | 182.63M |
| 10 | 21.08B | 12.9% | 421.64M | 149.60M |
Key risks
- Credit cycle turn: a rise in unemployment pushes net charge-offs back above 6% and forces reserve builds
- Partner concentration and renewal risk with large retailers, plus pressure on revenue-share terms
- Regulatory pressure on late fees, rate caps or deposit funding costs compressing net interest margin
Catalysts
- Continued improvement in delinquencies, allowing more reserve releases and buybacks
- Wins in the health and vet partner verticals (CareCredit, Vetspire) restarting loan-receivable growth